Clinical trials: Colitis
Clostridium Difficile Colitis
Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
Once the lab test is positive for c. diff, the investigators will order the patient to have PEG 3350 solution, one 8oz glass every ten minutes until 6 liters are gone, but if still not clear 2 more liters may be ordered.
- Trial name
- COLITIS (NCT01630096)
- Testing
- Nu-Lytely
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ascension Health
Ulcerative Colitis
A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis
The purpose of this study is to determine the pharmacokinetics (PK) and to assess safety and tolerability of a single dose of ASP3291 in subjects with ulcerative colitis.
- Trial name
- NCT01320332
- Testing
- ASP3291
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Telsar Pharma Inc.
Colitis, Ulcerative, Recurrence
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs.
- Trial name
- NCT00746447
- Testing
- mesalamine granules
- Where
- Germany
- Volunteers
- 648 people
- Sponsor
- Dr. Falk Pharma GmbH
Colitis, Ulcerative
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.
- Trial name
- NCT00747110
- Testing
- budesonide, mesalazine
- Where
- Germany
- Volunteers
- 343 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26…
- Trial name
- CAMPIII (NCT01004185)
- Testing
- Asacol 400 mg
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 39 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis.
- Trial name
- NCT00064441
- Testing
- OPC-6535 Tablets (drug)
- Where
- 23 sites in United States
- Volunteers
- 375 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis.
- Trial name
- NCT00064454
- Testing
- OPC-6535 Tablets (drug)
- Where
- 28 sites in United States
- Volunteers
- 375 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
- Trial name
- NCT00307827
- Testing
- Visilizumab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Abbott
Ulcerative Colitis
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a…
- Trial name
- NCT00209287
- Testing
- Observe patients with inactive ulcerative colitis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Ferring Pharmaceuticals
Mild to Moderate Ulcerative Colitis
Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyCol™)
This is a multi-center study in Ireland and United Kingdom to determine the effects, safety and tolerability of a drug called CyCol™ in improving mild to moderate ulcerative colitis (UC).
- Trial name
- NCT01033305
- Testing
- CyCol™
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 118 people
- Sponsor
- Sigmoid Pharma
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis
The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with…
- Trial name
- NCT00713310
- Testing
- Asacol 400 mg
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 83 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis
Children aged up to 18 years with moderately active Ulcerative Colitis (PUCAI:35-64) will receive one weekly Adacolumn® apheresis treatment over 5 consecutive weeks, followed by up to 3 optional Adacolumn® apheresis treatments…
- Trial name
- NCT00781638
- Testing
- Adacolumn®
- Volunteers
- 24 people
- Sponsor
- Otsuka Frankfurt Research Institute GmbH
Ulcerative Colitis
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis
Ulcerative colitis is characterized by abnormal activation of, and damage to, the colon epithelium, which is considered to be a central pathogenic mechanism.
- Trial name
- NCT00727324
- Testing
- bovine intestinal alkaline phosphatase (BIAP)
- Where
- 11 sites in Czechia, Italy
- Volunteers
- 22 people
- Sponsor
- AM-Pharma
Crohn's Disease, Colitis
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD).
- Conditions
- Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease
- Trial name
- NCT00072943
- Testing
- anti-Interferon-gamma monoclonal antibody
- Where
- 19 sites in United States, Canada
- Volunteers
- 175 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.
- Trial name
- NCT00279435
- Testing
- visilizumab
- Where
- 39 sites in United States, Australia and 13 more
- Volunteers
- 25 people
- Sponsor
- Facet Biotech
Severe Ulcerative Colitis
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability of visilizumab in patients with severe ulcerative colitis that has failed to respond to steroid therapy.
- Trial name
- NCT00267306
- Testing
- Visilizumab
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Facet Biotech
Ulcerative Colitis
Research Study in Patients With Severe Ulcerative Colitis
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat severe ulcerative colitis refractory to steroid therapy.
- Trial name
- NCT00032305
- Testing
- Visilizumab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Facet Biotech
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Ulcerative Colitis, Large Intestine
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
The participation in this clinical study will last approximately 21 weeks with a 1 week screening period and a 12 weeks treatment duration.
- Conditions
- Ulcerative Colitis, Large Intestine, Diarrhea, Abdominal Pain
- Trial name
- NCT01011322
- Testing
- LT-02
- Where
- 26 sites in Germany, Lithuania and 1 more
- Volunteers
- 156 people
- Sponsor
- Lipid Therapeutics GmbH